The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...

The study group consisted of 22 patients with STS treated with Trabectedin (Yondelis ®, PharmaMar, Madrid, Spain), and the demographic and clinical-pathological characterization at baseline are ...

SA ( ($PHMMF) ) has released its Q4 earnings. Here is a breakdown of the information Pharma Mar SA presented to its investors. Pharma ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

The CHMP also said it had started looking into its accelerated approval of PharmaMar’s Yondelis (trabectedin) for relapsed ovarian cancer, after a clinical trial was stopped prematurely because ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients ...

Corals contain bioactive compounds with anti-inflammatory and neuroprotective effects. Marine sponges have yielded promising compounds for chemotherapy, including trabectedin (Yondelis) used for soft ...